Hey Leute, wer kann mir mit Biotech weiterhelfen?
Seite 1 von 2 Neuester Beitrag: 27.04.04 04:50 | ||||
Eröffnet am: | 13.07.01 20:10 | von: Hartkore_Dia. | Anzahl Beiträge: | 34 |
Neuester Beitrag: | 27.04.04 04:50 | von: Eskimato | Leser gesamt: | 12.124 |
Forum: | Börse | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < | 2 > |
OK
Thanxxx
Hartkore_Diablo
Vertex, gefällt mir von den US-Werten am besten.
vertex würde ich derzeit noch meiden, haben zwar viele produkte, aber viele erst in phase IIa, dauert noch bis zum möglichen blockbuster, sieht man auch am kursverlauf sei april
qiagen würde ich nicht kaufen, da sehr teuer und wenig potential nach oben
cvtx, icos, imcl, pdli top-investments, natürlich nicht risikoarm
Echte Kursraketen sind derzeit Cypress Biosciences, Boston Biomedica !!!!!,
Bradley Pharmaceuticals, Interneuron Pharnaceuticals, Sicor,
derzeit gute Einstiegskurse bei VAXGEN und Ligand Pharmaceuticals.
100 % seit Jahresanfang mit steigender Tendenz.
abgeschmiert, weil Forschungskoopertionen gekündigt wurden.
Onyx Medikament Therex wurde mal als möglicher Blockbuster gehandelt, kommt aber
keinesfalls vor 2005 au den Markt.
Jetzt kommmt wieder Bewegung in die Aktie. Kein Risiko auf dem Niveau, aber
8 Dollar sind schnell drin.
Exelixis ähnliche Situation, überzeugt aber vom Chart mit steigenden Kursen
und Umsätzen. Noch für 13 Dollar zu haben.
Boden gefunden., heute an der Nasdaq + 10 % auf 5 Dollar, Kursziel mindestens 8 Dollar.
Aktien an der Nasdaq gehandelt. Kurs aktuell bei 5,77, denke 8 Dollar sitzen dieses Jahr drin.
Bei DUSA Pharmaceuticals ist es noch zu ruhig, keine Umsätze, nur 50 Tausend
gehandelte Stücke.
Da sind wahrscheinlich noch mehr als 8 $ drin. Aber Vorsicht ist die Mutter der Porzellankiste ...
R.
mir zu helfen. Ich kriege meine Comdirect-Diagramme nicht ins Board gestellt bzw. reinkopiert.
Hast Du meinen Thread zu BRPX gelesen, klappt wunderbar.
Leider keine Kohle um heute PLXX oder AMCC zu kaufen.
2. "Eigenschaften" anklicken
3. Feld "Adresse (URL)" mit Maus markieren (ggf. dabei scrollen)
4. Zeiger auf markiertes Feld und rechte Maustaste klicken.
5. "Kopieren" anklicken
Jetzt auf ARIVA eingeben:
1. Zeile freilassen
2. (siehe unten) Eingabe: < IMG SRC" (aber ohne Leerzeichen vor dem "I")
3. jetzt rechte Maustaste klicken und dann "Einfügen" anklicken
4. jetzt Eingabe: ">
Beispiel für obigen Chart zu ONXX: (Bitte erstes Leerzeichen wegdenken.)
< IMG alt="" title="" rel="nofollow" src="http://chart.bigcharts.com/bc3/quickchart/...93&mocktick=1&rand=5088" style="max-width:560px" >
Liest sich komplizierter als es ist.
Bios machen übrigens wieder Spaß.
R.
BPRX-Thread. Muss jetzt allerdings zur Nachtschicht.
Onyx Pharmaceuticals to Present at Needham & Company 2nd Annual Biotechnology Conference
RICHMOND, Calif., Jun 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Onyx
Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the
Needham & Company 2nd Annual Biotechnology Conference in New York City on
Friday, June 6, at 10:30 a.m. Eastern Time. Investors may access a live audio
webcast of the presentation at http://www.twst.com/econf/mm/needham5/onxx.html.
We recommend logging on 15 minutes early in order to register and download any
necessary software.
Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer
therapies and has proprietary technologies that target the molecular basis of
cancer. The company is developing small molecule drugs, including BAY 43-9006 in
collaboration with Bayer. In addition, the company's preclinical portfolio
includes proprietary therapeutic viruses and Armed Therapeutic Virus(TM)
products. For more information about Onyx's pipeline and activities, visit the
company's website at www.onyx-pharm.com.
This press release, or the webcast, may contain certain forward-looking
statements regarding the development of potential human therapeutic products
that involve a number of risks and uncertainties. Actual events may differ from
the company's expectations. The timeline for clinical activity, results of
pending or future clinical trials, and changes in the status of the company's
collaborative relationships, as well as the risk factors listed from time to
time in the company's periodic reports filed with the Securities and Exchange
Commission, including but not limited to its Annual Report on Form 10-K, may
affect the actual results achieved by the company.
SOURCE Onyx Pharmaceuticals, Inc.
CONTACT: Julianna Wood of Onyx Pharmaceuticals, Inc., +1-510-262-8757
Boston Biomedica Awarded Tenth US Patent for Pressure Cycling Technology (PCT)
WEDNESDAY, JUNE 04, 2003 9:48 AM
- PR Newswire
WEST BRIDGEWATER, Mass., Jun 04, 2003 /PRNewswire-FirstCall via Comtex/ -- Boston Biomedica, Inc. (BBII) today announced that the United States Patent and Trademark Office has issued Patent No. 6,569,672 to the Company for the design and use of its "Pressure Cycling Reactor" for the control of pressure sensitive reactions. This patent is an extension of previous Pressure Cycling Technology ("PCT") patents awarded to Boston Biomedica. PCT uses pulses of high pressure to reversibly turn on and off enzymatic reactions under very well defined and controlled conditions. The new patent describes a pressure cycling apparatus in which movement of fluids in and out of the reaction chamber can be precisely regulated by a series of valves under pressurized conditions. Such an enhancement would promote the study of protein-protein interactions, as it could both allow reagents to be added during a reaction, as well as allow the sampling of products from the reaction mixture, all under controlled pressure and temperature conditions.
This is the tenth patent issued to BBI for Pressure Cycling Technology. Previously issued patents included the instrumentation and methods needed to carry out the PCT process, with applications in extracting nucleic acids and proteins from cells and tissues, inactivation of viruses in plasma while retaining its therapeutic properties, purification of proteins and nucleic acids, DNA sequencing, and control of nucleic acid hybridizations.
"PCT is a novel, platform-based technology as evidenced by the continued expansion of our patent estate into additional applications," said Kevin Quinlan, President and Chief Operations Officer of Boston Biomedica. "This new patent represents another tool for the control of enzymatic reactions and may have future applications in diagnostics, therapeutics, and other areas of life sciences. We are currently seeking partners to help exploit these additional applications. Meanwhile, we will continue our current focus on the use of PCT for the extraction of nucleic acids, proteins, and small molecules from difficult-to-lyse tissues and cells, as we and our collaborators find new applications and advantages for this system in sample preparation."
About Boston Biomedica, Inc.
BBI provides products and services to the diagnostics and life sciences industries to evaluate, monitor, and ensure the quality of infectious disease test results, to improve the preparation of specimens for genomic/proteomic testing, and to safely store and retrieve rare and valuable biological specimens. We also manufacture reagents used in test kits and provide a broad range of routine and esoteric research services to governments and industry. BBI has facilities in three states, and conducts research in new applications for our patented Pressure Cycling Technology (PCT). In 2000, we launched Panacos Pharmaceuticals, and the Company maintains a significant passive investment in this novel antiviral drug development company.
Forward Looking Statement
Statements contained in this news release that state the Company's or management's intention, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the possibility that PCT may not become a cost- effective method for regulating biomolecules; that, due to difficulties in the development of the technology, BBI may not be successful in developing pressure cycling technology into commercially viable products or services; that pressure cycling technology may not be adaptable to any other commercially viable applications; that certain pressure cycling applications may not fall within the claims of the Company's ten issued patents; that the Company may not succeed in finding partners to help exploit PCT, and that individuals and groups utilizing such PCT procedures may not be required to license such technology from BBI. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and the Company's Quarterly Reports on Form 10-Q for the three months ended March 31, 2003. Copies of these documents may be obtained by contacting the Company or the SEC.
Visit us at our website http://www.bbii.com
Gruss E.
Und bei allen CYPT Diskussionen an Bord, CYPB gibt es ja auch noch und und und...
Gruss E.
http://chart.bigcharts.com/bc3/quickchart/...78&mocktick=1&rand=7319"
http://chart.bigcharts.com/bc3/quickchart/...69&mocktick=1&rand=8469"